Spinelli Giuseppe, Torresetti Matteo, Lazzeri Davide, Zhang Yi Xin, Arcuri Francesco, Agostini Tommaso, Grassetti Luca
From the *Maxillofacial Surgery Unit, CTO, Careggi University Hospital, Florence, Italy; †Department of Plastic and Reconstructive Surgery, Marche Polytechnic University Medical School, Regional Hospital, Ancona, Italy; ‡Plastic and Reconstructive Surgery Unit, Hospital of Pisa, Pisa, Italy; and §Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Craniofac Surg. 2014 May;25(3):788-92. doi: 10.1097/SCS.0000000000000833.
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is the most serious complication of bisphosphonates therapy. Despite that several treatment modalities have been described, aggressive surgical treatment approach with wide bone resection and vascularized microsurgical reconstruction are controversial. The aim of this study was to evaluate the clinical outcome of 8 new cases of BRONJ treated with radical resection and mandibular reconstruction with fibula free flap, to enforce the evidence about the reliability of this treatment option.
Retrospective data of 8 patients with BRONJ who underwent segmental mandibulectomy and reconstruction with osteocutaneous fibula free flap from January 2004 to January 2008 were collected, including 6 patients with stage 3 BRONJ and 2 patients with recalcitrant stage 2 BRONJ.
All patients were white, with a mean age of 64.7 years (range, 53-77 y), and 62.5% were women. All bisphosphonates were administered intravenously, and all patients had mandibular localization. The mean period of follow-up was 28.9 months. No flap loss or minor complications and no BRONJ recurrence were observed. All patients were able to ambulate pain-free.
Despite initial concerns regarding reliability of the mandibular free-flap reconstruction after BRONJ, this method seems to be a safe and feasible option in cancer patients with reasonable life expectancy, with complete BRONJ resolution and life quality improvement. Our findings confirm data previously published by other authors, without complication and with a much longer median follow-up time.
双膦酸盐相关颌骨坏死(BRONJ)是双膦酸盐治疗最严重的并发症。尽管已经描述了几种治疗方式,但广泛骨切除和带血管显微外科重建的积极手术治疗方法仍存在争议。本研究的目的是评估8例采用根治性切除和游离腓骨瓣下颌骨重建治疗的BRONJ新病例的临床结果,以强化关于这种治疗选择可靠性的证据。
收集2004年1月至2008年1月期间8例接受节段性下颌骨切除术并用游离腓骨皮瓣重建的BRONJ患者的回顾性数据,其中包括6例3期BRONJ患者和2例顽固性2期BRONJ患者。
所有患者均为白人,平均年龄64.7岁(范围53 - 77岁),62.5%为女性。所有双膦酸盐均通过静脉给药,所有患者均为下颌骨受累。平均随访期为28.9个月。未观察到皮瓣丢失或轻微并发症,也未观察到BRONJ复发。所有患者均能无痛行走。
尽管最初对BRONJ后下颌游离皮瓣重建的可靠性存在担忧,但这种方法对于预期寿命合理的癌症患者似乎是一种安全可行的选择,可使BRONJ完全消退并改善生活质量。我们的研究结果证实了其他作者先前发表的数据,且无并发症,随访中位时间更长。